Back to top

crispr: Archive

Zacks Equity Research

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

VRTXPositive Net Change BLUENegative Net Change EDITPositive Net Change CRSPPositive Net Change